CNS Pharmaceuticals Inc. CNSP Archives - Page 10 of 23

MondayOct 17, 2022 1:05 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

FridayOct 14, 2022 12:05 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful,…

MondayOct 10, 2022 11:57 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run. The event is taking place on Saturday, Nov. 5, 2022, in Los Angeles, California. “The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally and the optimism and strength with which they have…

FridayOct 07, 2022 11:11 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio release covers CNS Pharmaceuticals’ recent announcement that highlights the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”), one of the…

MondayOct 03, 2022 12:55 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. ‘With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ noted CNS CEO John Climaco. GBM’s median survival from initial diagnosis is less than 15…

WednesdaySep 28, 2022 2:02 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, the first European clinical trial sites in France and Spain are now open and actively enrolling patients. “Our primary focus continues to be on advancing the clinical development of…

FridaySep 23, 2022 12:12 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the following event at 1:00 p.m. ET on Wednesday, Sept. 28, 2022: Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (“GBM”). As part of the virtual event, Climaco will discuss the company’s ongoing potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. Interested parties should visit https://ibn.fm/ktCnW…

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each year The current standard of care for GBM is ineffective for approximately 60% of patients Initial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the…

FridaySep 16, 2022 1:43 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of…

TuesdaySep 13, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas Glioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosis CNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP